// App-Quantinova.ai

TPS4132 : A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Researchers

Presenter

  • Johanna C. Bendell

Principal Investigators

  • Alexander Starodub

  • Zev A. Wainberg

  • Meihua Wu

  • Douglas Werner

  • Julia D. Maltzman

  • Manish A. Shah

Medical Centers

  • Sarah Cannon Research Institute, Nashville, TN

  • Indiana University Health Center for Cancer Care, Goshen, IN

  • David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

  • Gilead Sciences, Inc., Foster City, CA

  • Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY

Locations

  • United States

Companies

  • Gilead Sciences, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Adrucil injection

  • leucovorin

  • mFOLFOX6

  • GS5745

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02545504

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved